tislelizumab
Jump to navigation
Jump to search
Indications
- as monotherapy or adjunct to chemotherapy* for treatment of squamous cell carcinoma of the lung
- as monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC)[2]
Dosage
- 200 mg administered intravenously every 3 weeks
Mechanism of action
- high binding affinity to the PD-1 receptor
- specifically engineered to minimize Fc-gamma receptor binding on macrophages
- this diminishes antibody-dependent phagocytosis, a mechanism of T-cell clearance & potential resistance to anti-PD-1 therapy
- antitumor with advanced lung cancers, regardless of PD-L1 expression
More general terms
References
- ↑ Wang J, Lu S, Yu X et al Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer. A Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online April 1, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33792623 https://jamanetwork.com/journals/jamaoncology/fullarticle/2777901
- ↑ 2.0 2.1 Bankhead C New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer. Questions about generalizability of results with China-developed therapies. MedPage Today April 14, 2021 https://www.medpagetoday.com/meetingcoverage/aacr/92100
Zhou C et al Results from RATIONALE 303: A global phase III study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. American Association for Cancer Research (AACR) 2021; Abstract CT039